Reirradiation practices for children with diffuse intrinsic pontine glioma.
diffuse intrinsic pontine glioma
reirradiation
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
Diffuse intrinsic pontine gliomas (DIPGs) are a leading cause of brain tumor deaths in children. Current standard of care includes focal radiation therapy (RT). Despite clinical improvement in most patients, the effect is temporary and median survival is less than 1 year. The use and benefit of reirradiation have been reported in progressive DIPG, yet standardized approaches are lacking. We conducted a survey to assess reirradiation practices for DIPG in North America. A 14-question REDCap survey was disseminated to 396 North American physicians who care for children with CNS tumors. The response rate was 35%. Participants included radiation-oncologists (63%; 85/135) and pediatric oncologists/neuro-oncologists (37%; 50/135). Most physicians (62%) treated 1 to 5 DIPG patients per year, with 10% treating more than 10 patients per year. Reirradiation was considered a treatment option by 88% of respondents. Progressive disease and worsening clinical status were the most common reasons to consider reirradiation. The majority (84%) surveyed considered reirradiation a minimum of 6 months following initial RT. Doses varied, with median total dose of 2400 cGy (range, 1200-6000 cGy) and fraction size of 200 cGy (range, 100-900 cGy). Concurrent use of systemic agents with reirradiation was considered in 46%, including targeted agents (37%), biologics (36%), or immunotherapy (25%). One-time reirradiation was the most common practice (71%). Although the vast majority of physicians consider reirradiation as a treatment for DIPG, total doses and fractionation varied. Further clinical trials are needed to determine the optimal radiation dose and fractionation for reirradiation in children with progressive DIPG.
Sections du résumé
BACKGROUND
BACKGROUND
Diffuse intrinsic pontine gliomas (DIPGs) are a leading cause of brain tumor deaths in children. Current standard of care includes focal radiation therapy (RT). Despite clinical improvement in most patients, the effect is temporary and median survival is less than 1 year. The use and benefit of reirradiation have been reported in progressive DIPG, yet standardized approaches are lacking. We conducted a survey to assess reirradiation practices for DIPG in North America.
METHODS
METHODS
A 14-question REDCap survey was disseminated to 396 North American physicians who care for children with CNS tumors.
RESULTS
RESULTS
The response rate was 35%. Participants included radiation-oncologists (63%; 85/135) and pediatric oncologists/neuro-oncologists (37%; 50/135). Most physicians (62%) treated 1 to 5 DIPG patients per year, with 10% treating more than 10 patients per year. Reirradiation was considered a treatment option by 88% of respondents. Progressive disease and worsening clinical status were the most common reasons to consider reirradiation. The majority (84%) surveyed considered reirradiation a minimum of 6 months following initial RT. Doses varied, with median total dose of 2400 cGy (range, 1200-6000 cGy) and fraction size of 200 cGy (range, 100-900 cGy). Concurrent use of systemic agents with reirradiation was considered in 46%, including targeted agents (37%), biologics (36%), or immunotherapy (25%). One-time reirradiation was the most common practice (71%).
CONCLUSION
CONCLUSIONS
Although the vast majority of physicians consider reirradiation as a treatment for DIPG, total doses and fractionation varied. Further clinical trials are needed to determine the optimal radiation dose and fractionation for reirradiation in children with progressive DIPG.
Identifiants
pubmed: 33664971
doi: 10.1093/nop/npaa063
pii: npaa063
pmc: PMC7906270
doi:
Types de publication
Journal Article
Langues
eng
Pagination
68-74Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Neurooncol. 2018 Dec;140(3):629-638
pubmed: 30206764
J Neurooncol. 2014 Jun;118(2):305-312
pubmed: 24696052
Front Oncol. 2015 Oct 21;5:237
pubmed: 26557503
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):113-8
pubmed: 19647954
Neuro Oncol. 2019 Mar 18;21(4):547-557
pubmed: 30452715
Lancet Oncol. 2006 Mar;7(3):241-8
pubmed: 16510333
Neuro Oncol. 2015 Jan;17(1):160-6
pubmed: 24903904
Cancer. 2011 Nov 1;117(21):4977-82
pubmed: 21495027
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1541-8
pubmed: 22245198
J Neurooncol. 2018 Jul;138(3):679-680
pubmed: 29767306
World Neurosurg. 2016 Sep;93:485.e11-4
pubmed: 27422681
Pediatr Blood Cancer. 2018 Jun;65(6):e26988
pubmed: 29369515
Front Oncol. 2012 Dec 28;2:205
pubmed: 23293772
Am J Clin Oncol. 2012 Feb;35(1):51-7
pubmed: 21297433
Cureus. 2017 Aug 18;9(8):e1580
pubmed: 29057192
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):144-148
pubmed: 30610915
Eur J Cancer. 2017 Mar;73:38-47
pubmed: 28161497